PYC THERAPEUTICS LIMITED (PYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PYC - PYC THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.17

07 Oct
2024

0.000

OPEN

$0.17

0.000

HIGH

$0.18

1,076,335

LOW

$0.17

TARGET
$0.17
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PYC: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 0.7 - 0.7 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx1.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-38.6 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-69.70 %
Return on Invested Capital xxxxxxxxxxxxxxx-69.10 %
Return on Assets xxxxxxxxxxxxxxx-58.76 %
Return on Equity xxxxxxxxxxxxxxx-69.70 %
Return on Total Capital xxxxxxxxxxxxxxx-108.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-38.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx67 M
Price To Book Value xxxxxxxxxxxxxxx6.96

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.3 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx59 M
Research & Development xxxxxxxxxxxxxxx56 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

07/08/2024

1

Speculative Buy

$0.17

0%

Bell Potter is encouraged by the second clinical data update from PYC Therapeutics reported for VP-001, targeting retinitis pigmentosa type 11, showed  with two out of three patients demonstrating efficacy signals after a single 30µg dose.

The broker points to potentially more good news flow as data from a higher 75µg dose cohort is expected soon.

There are no changes to the analyst's earnings forecasts. A Speculative Buy rating and 17c target retained.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.70 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

01/07/2024

1

Overweight

$0.37

117.65%

As Regulus Therapeutics competes against PYC Therapeutics' asset PYC-003 with its drug asset RGLS8429, Wilsons reviews updated data for the latter's Phase I MAD trial in autosomal dominant polycystic kidney disease (ADPKD).

The Regulus share price reacted negatively on concerns whether the data are clear enough from a regulatory standpoint to continue to progress to a Phase II, explains the broker.

The outcomes of Regulus’ end-of-Phase I meeting with the FDA in the December quarter should provide greater clarity.

The broker maintains an Overweight rating and 37c target.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.80 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.90 cents.
Access Extra Coverage Research History >

PYC STOCK CHART

FNArena News on PYC

1
Australian Broker Call *Extra* Edition – Sep 26, 2024

Sep 26 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 23, 2024

Sep 23 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 20, 2024

Aug 20 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 08, 2024

Aug 08 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 01, 2024

Aug 01 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps